1 citations
,
October 2006 in “Oncology times” Finasteride improves prostate cancer detection in PSA test.
March 2011 in “European Urology Supplements” Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.
10 citations
,
February 2022 in “Cancers” More research and guidelines are needed for managing prostate cancer in people with high-risk genetic mutations.
4 citations
,
November 2022 in “British Journal of Cancer” Men with melanoma have a higher risk of later being diagnosed with prostate cancer.
June 2023 in “Journal of Liaquat University of Medical & Health Sciences” Higher PSA levels are linked to more hirsutism in women with PCOS.
November 2011 in “InTech eBooks” Prostate cancer risk is not linked to blood testosterone levels.
6 citations
,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
34 citations
,
January 2000 in “Journal of Andrology” CAG repeat polymorphism and prostate zone volume are not reliable markers of long-term androgen sensitivity.
November 2012 in “The Journal of Urology” Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.
February 2007 in “Journal watch” Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.
23 citations
,
January 2014 in “International Journal of Biological Sciences” African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.
41 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
3 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
153 citations
,
April 2009 in “Urology” Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.
17 citations
,
July 2016 in “The Prostate” Metformin may lower PSA levels, possibly affecting prostate cancer development.
Women with androgenetic alopecia (hair loss) have normal prostate specific antigen levels but higher testosterone levels.
February 2007 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.
2 citations
,
July 2021 in “The Journal of Sexual Medicine” Gene expression differences in PFS patients suggest a potential organic cause for symptoms.
August 2015 in “International Journal of Genetics and Molecular Biology” Certain genetic markers may increase or decrease prostate cancer risk.
39 citations
,
February 2011 in “The Prostate/The prostate” Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.
September 2019 in “Human Andrology” Higher serum androgens contribute to male pattern baldness.
13 citations
,
August 2018 in “Clinical Chemistry” Total testosterone levels can help diagnose androgen-producing tumors and hyperandrogenism in women.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
March 2013 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Prostate cancer screening doesn't significantly reduce death rates and has risks like overdiagnosis and side effects.
January 2024 in “International Journal of Trichology” PON1 levels might indicate hair loss severity, but other health factors can affect this.
Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.
October 2015 in “Prostate Cancer” Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
16 citations
,
December 2010 in “European Journal of Obstetrics & Gynecology and Reproductive Biology” Normal levels for certain hormones in Chinese women of reproductive age were identified.
April 2012 in “The Journal of Urology” Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.